Dr. Pleyer on the Safety, Efficacy of Ibrutinib Plus Short-Course Fludarabine in CLL

September 29, 2020

Partner | Cancer Centers

Christopher Pleyer, MD, discusses results from a phase 2 study with ibrutinib plus short course fludarabine in previously untreated patients with chronic lymphocytic leukemia.

Christopher Pleyer, MD, The National Heart, Lung, and Blood Institute, discusses results from a phase 2 study with ibrutinib (Imbruvica) plus short course fludarabine in previously untreated patients with chronic lymphocytic leukemia (CLL).

After 2 years of follow-up, when the primary efficacy analysis of the trial was released, 44% of patients achieved a complete remission (CR) at 2 years with the combination of ibrutinib and short-course fludarabine, says Pleyer. Notably, this rate is slightly higher than what is typically seen with ibrutinib as a single agent. It is important to note that this was not a randomized trial. Preliminary results with the combination demonstrated encouraging CR rates, adds Pleyer.

The combination was also well tolerated, and no additional toxicities were reported, adds Pleyer. Specifically, with fludarabine, depletion and long-term depletion of T cells is a concern; however, this was not shown in the study. Additionally, investigators did not observe a significant increase in the number of infections in patients on the study who received the regimen, concludes Pleyer.


x